CTX320 / CRISPR Therap - LARVOL DELTA

CTX320, targeting LPA (GlobeNewswire) - "The Phase 1 trial is enrolling patients and dose-finding is ongoing. An update is now expected in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) landscape."

P1 data • Trial status • Cardiovascular

CTX320: An Investigational in vivo CRISPR-Based Therapy Efficiently and Durably Reduces Lipoprotein (a) Levels in Non-Human Primates After a Single Dose (AHA 2023) - "CTX320 was well-tolerated in NHPs and resulted in high levels of editing in the liver that led to long-lasting reduction in plasma Lp(a). This data suggests CTX320 could be used to reduce plasma Lp(a) levels in humans."

Preclinical • Atherosclerosis • Cardiovascular • Dyslipidemia